FDA Reaffirms Heparin Import Documentation Requirements Across Crude, API, and LMWH Product Categories

Contamination history continues to shape FDA's posture on heparin imports: every shipment of crude heparin, heparin sodium API, finished dosage forms, and low molecular weight heparin (LMWH) must arrive with a defined analytical package or risk delayed entry review. For QA directors and regulatory affairs leads managing import operations, the agency's current guidance leaves little interpretive room on what constitutes an acceptable submission.

For crude heparin, importers must provide SAX-HPLC chromatograms, a 500 MHz 1D-¹H-NMR spectrum with an expansion plot of the 1.8–2.3 ppm region, and ¹H-NMR data for both the USP Reference Standard and USP System Suitability Solutions. The test method must comply with the USP and National Formulary monograph covering analysis by ¹H NMR, capillary electrophoresis, and strong-anion-exchange HPLC for oversulfated chondroitin sulfate (OSCS) contamination, the adulterant linked to patient deaths in prior heparin safety incidents.

Heparin sodium API and finished dosage form submissions carry a parallel but distinct requirement set: a Certificate of Analysis for the batch, a ¹H-NMR spectrum per current USP method with the 1.8–3.0 ppm region expanded, and an HPLC-SAX chromatogram. Where testing deviates from USP specifications, importers must also submit a standard chromatogram spiked with OSCS and analyzed concurrently, a method suitability demonstration FDA uses to assess whether submitted results were generated with validated methods.

LMWH importers face an additional layer: the analytical file must incorporate data for the heparin sodium API used to manufacture the LMWH API, consolidated into a single electronic file where possible. The Certificate of Analysis for the LMWH API batch must include explicit certification that no OSCS is present. The ¹H-NMR and HPLC-SAX requirements mirror those for heparin sodium API, and the same OSCS-spiked chromatogram provision applies when testing falls outside USP specifications.

FDA conducts case-by-case testing across all heparin forms and expects full alignment with current USP specifications and its own regulatory standards. Incomplete analytical packages do not automatically trigger refusal, but they slow entry review, a supply-chain consequence that becomes operationally significant for facilities managing lean heparin inventory or time-sensitive production schedules.

Regulatory teams preparing import submissions should treat the OSCS spiked-chromatogram requirement as a standing obligation whenever non-USP methods are in use, given FDA's stated intent to evaluate method validation through that data point.

Source: FDA, Human Drug Imports via FDA.gov, 2026-06-05.